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OBJECTIVES: The objectives of this study were to determine the sensitivity of ovarian cancer (OC) cell lines (TOV-
21G and SKOV-3) to cisplatin and to the recombinant human TRAIL (rhTRAIL), and to evaluate the expression
profile of TNFRSF10B, TNFRSF10C, TP53TG5, MDM2, BAX, BCL-2 and CASPASE-8 genes and their participation in
the resistance/susceptibility mechanism of these tumor cell lines.
METHODS: To determine the IC50 values associated with Cisplatin and rhTRAIL, inhibition of cell growth was
observed using MTT assays in two human OC cell lines (SKOV-3 and TOV-21G). The analysis of gene expression
was performed using quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: Both cell lines had different susceptibility profiles to the tested drugs. In the SKOV-3 cell line, the IC50
values for cisplatin and for rhTRAIL were 270.83 ug/mL and 196.5 ng/mL, respectively. The same concentrations
were used for TOV-21G. Different gene expression profiles were observed in each tested cell line. CASPASE-8
and TNFRSF10B expression levels could predict the response of both the cell lines to rhTRAIL alone or the
response to a combination of rhTRAIL and cisplatin. In addition, we observed a relationship between BCL-2 and
BAX expression that may be helpful in estimating the proliferation rate of the OC cell lines.
CONCLUSION: SKOV-3 and TOV-21G respond differently to cisplatin and rhTRAIL exposure, and expression of
CASPASE-8 and TNFRSF10B are good predictors of responses to these treatments.
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’ INTRODUCTION
Ovarian cancer (OC) is a highly fatal form of gynecological
cancer characterized as the 7th most common cause of cancer
in women worldwide (1,2). In 2018, OC was estimated to be
responsible for 295,414 new cases of cancer and 184,799
deaths worldwide (3). In Brazil, OC is 8th most common type
of cancer in women. The estimated number of new OC cases
in 2018-2019 was 6,150 (4) with an associated risk of 5.79
cases per 100,000 women.
The high mortality rates of OC is partially due to the
inefficient detection of the disease in its initial stage, resulting
in the diagnosis of 75% of the patients in the advanced stages
(5). Chemotherapy involving platinum and taxanes has been
used to treat OC for the last four decades. Although most
patients show an initial response to treatment, the disease
recurs within two years of treatment in 60%-80% of the
patients (6). The major factor that limits the efficiency of
chemotherapy is resistance acquisition (7). Some mechanisms
proposed to contribute to resistance include decreased drug
capture by cells, increased drug efflux, and increased DNA
repair (8). In addition, characteristics such as self-renewal,
chemoresistance, anchorage-independent growth, and apop-
tosis resistance have been associated with drug resistance,
cancer progression, and tumor recurrence (9-11). However,
the molecular mechanisms underlying resistance to che-
motherapy have not been fully understood (12). Recent
advances in adjuvant chemotherapy for OC, such as
combining platinum with paclitaxel, have increased patient
survival, however complete remission remains rare, and
the success of recurrent cancer treatments is limited. Thus,
new therapeutic modalities for the treatment of OC are neces-
sary (13,14).DOI: 10.6061/clinics/2020/e1492
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The TRAIL (TNF-related apoptosis-inducing ligand) recep-
tor pathway has been a focus of studies that are aimed at
developing a new strategy to combat OC resistance to cisp-
latin treatment (15). TRAIL can selectively induce apoptosis
in tumor cells with little toxicity to normal cells (16). The TRAIL
protein can attach to four cell-surface receptors. TNFRSF10A
(TRAIL-R1/DR4) and TNFRSF10B (TNFRSF10B/DR5) induce
apoptosis, however TNFRSF10C (TNFRSF10C/DcR1) does not
contain an intracytoplasmic death domain and TNFRSF10D
(TRAIL-R4/DcR2) contains a truncated death domain, resul-
ting in the latter two being unable to transmit apoptotic
signals (17). Data on the involvement of these receptors
in apoptosis resistance in OC remain scarce. Despite the
heterogeneity of molecular profiles and histological pheno-
types of OC, most cases are treated indiscriminately (16,18).
The present study aims to determine the sensitivity of OC
cell lines (TOV-21G and SKOV-3) to cisplatin and to the
recombinant human TRAIL (rhTRAIL), to evaluate the
expression of TRAIL receptors (TNFRSF10B and TNFRSF10C),
repair genes (TP53TG5 and MDM2), and apoptotic cascade
genes (BAX, BCL-2, and CASPASE-8) in these cell lines, and
to analyze their participation in drug resistance and drug
susceptibility.
’ METHODS
Cell Lines
TOV-21G (Cat. #CRL-11730t) and SKOV-3 (Cat. #CRL-
7566t) were acquired from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA). TOV-21G was cultivated
in the Dulbecco’s Modified Eagle’s Medium - High Glucose,
supplemented with 15% fetal bovine serum. The SKOV-3 line
was cultivated in the McCoy’s 5A (Modified) medium
supplemented with 10% fetal bovine serum. Both cell lines
were incubated at 37oC with 5% CO2.
Cell Survival Analysis
The TOV-21G and the SKOV-3 cell viabilities in the
presence of cisplatin and rhTRAIL were determined using
the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bro-
mide (MTT) method. Cells were plated in 96-Well cell culture
plates (1.0x105 cells/well) in triplicate and incubated for 24h
at 37oC with 5% CO2. After 24h, the wells were washed with
1X PBS and the cells were treated with varying concentra-
tions of cisplatin (275 ug/mL-100 ug/mL) and rhTRAIL
(600 ng/mL-0.78 ng/mL). Non-treated cells were used as
experimental controls. After 24h, MTT solution was added to
the plate (0.5 mg/mL final concentration), cells were incu-
bated for 3h and the absorbance at 540 nm was measured
using a Spectramax M5e. The concentration of each drug that
inhibited the viability of 50% of the cells (IC50) from each cell
line was calculated using an Origin 8.5.1 software.
Total RNA extraction and reverse transcription
Total RNA was extracted from untreated control cells and
cells treated with cisplatin, rhTRAIL or a combination of
each drug (IC50) using TRIzol
s (Invitrogen TM, USA) accor-
ding to the manufacturer’s instructions. The total RNA con-
centration and the 260/280 absorbance ratio were measured
using the NanovueTM Plus Spectrophotometer (GE Heath-
care Life, USA) microvolume spectrophotometer, and RNA
integrity was evaluated by 1% agarose gel electrophoresis.
Total RNA was then treated with RNase-free DNase Sets
(Qiagen) and 2 mg of RNA was used for complemen-
tary DNA (cDNA) synthesis using the M-MLV Reverse
Transcriptases kit (Sigma), according to the manufacturer’s
instructions.
Gene expression analysis
The expression of TNFRSF10B, TNFRSF10C, TP53TG5,
MDM2, BAX, BCL-2, and CASPASE-8 genes was evaluated
by quantitative real time polymerase chain reaction (qRT-
PCR), using the PowerUpt SYBRs Green Master Mix,
according to the manufacturer’s instructions. TBP and RPS26
genes were included as control genes for normalization. The
primers used in this study have been shown in Table 1.
Control samples representing total RNA without reverse
transcription were included in each assay. PCR reactions
followed the conditions outlined in Table 1 according to the
manufacturer’s instructions. Data was collected using the
Mx3005Ps qPCR System (Stratagene). The 2(-Delta C(T))
method (16) was used to quantify the relative expression
levels of each target gene.
Statistical Analysis
Data were analyzed using the SPSS 18.0 software package
(SPSS Inc., Chicago, Illinois, USA). Differences in the gene
expression were statistically evaluated using the non-para-
metric Kruskal-Wallis and the Levene tests. Differences were
considered statistically significant when po0.05. Clustering
analysis was performed using the UPGMA method and the
Table 1 - Information about primers used in qRT-PCR.
Gene
symbol*
Genetic information Primers sequence (50-30) Primer concentration
(nM)
Melting
temperature
TNFRSF10B NM_003842.5 FW GGGAGCCGCTCATGAGGAAGTTG RV
GGCAAGTCTCTCTCCCAGCGTCTC
250FW/200RV 60oC
TNFRSF10C NM_003841.4 FW GTTTGTTTGAAAGACTTCACTGTG RV
GCAGGCGTTTCTGTCTGTGGGAAC
200FW/200RV 60oC
CASPASE-8 NM_001080125.1 FW AGAGCCAGGGTGGTTATTGAA RV GCAGTCTCCGAGTCCCCTA 250FW/200RV 64oC
BCL-2 NM_000633.2 FW GAGTAAATCCATGCACCTAAACC RV TGCAAATTCTACCTTGGAGGG 250FW/200RV 60oC
TBP NM_003194.5 FW TGCACAGGAGCCAAGAGTGAA RV CACATCACAGCTCCCCACCA 200FW/200RV 60oC
MDM2 NM_001367990.1 FW AGATCCTGAGATTTCCTTAGCTGACT RV
TCTCACGAAGGGTCCAGCATCT
250FW/250RV 58oC
TP53TG5 NM_014477.3 FW ACTTGTCGCTCTTGAAGCTA RV GATGCGGAGAATCTTTGGAAC 350FW/300RV 55oC
BAX NM_138761.4 FW TGCTAGCAAACTGGTGCTCAA RV GCCCATGATGGTTCTGATCAGCT 150FW/100RV 59oC
RPS-26 NG_023201.1 FW CGTGCTTCCCAAGCTGTACGTGA RV CGATTCCGGACTACCTTGCTGTG 200FW/250RV 64oC
*Gene symbol and name according to the HUGO Gene Nomenclature Committee (HGNC) – the European Bioinformatics Institute (EMBL-EBI)
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Euclidian distance was calculated using the BioNumerics
software version 7.5 (Applied Maths, Sint-Martens-Latem,
Belgium).
’ RESULTS
Cell Viability Analysis
MTT assays were used to evaluate the effects of cisplatin
and rhTRAIL (24-h exposure) on the viability of the SKOV-3
and the TOV-21G cell lines. All cisplatin concentrations
tested reduced the viability of SKOV-3 cells, with the IC50
being 275 ug/mL (Figure 1A). Concentrations of rhTRAIL in
the range of 0.78 ng/mL to 25 ng/mL permitted cell
proliferation, while concentrations above 50 ng/mL inhib-
ited cell growth, with an IC50 close to 200 ng/mL (Figure 1
B). Using the Origin statistics program, IC50 values were
calculated as 270.83 ug/mL for cisplatin and 196.5 ng/mL
for rhTRAIL. In addition, all tested concentrations of cisp-
latin reduced the TOV-21G cell viability, despite variation in
the assays (Figure 1A). Although most of the tested rhTRAIL
concentrations reduced the TOV-21G cell viability, none
inhibited cell growth by 50% (Figure 1B). Thus, we decided
to use the IC50 values associated with cisplatin and rhTRAIL
treatment of the SKOV-3 cells for experiments with TOV-21G
cells in order to compare the effects of these drugs on each
cell line.
Different ratios of cisplatin and rhTRAIL at IC50 were used
to evaluate the effect of combining these drugs on the SKOV-
3 cell viability. Upon treatment with a 1:1 ratio of cisplatin:
rhTRAIL, the cell viability was found to be 28.49%. This cor-
responded to a strong synergistic effect, since the cell density
was almost half of that observed when the drugs were used
separately. The IC50 associated with combining the drugs
could not be statistically calculated. Thus, in order to
evaluate the effect of combined cisplatin-rhTRAIL treatment
on gene expression, we opted to consider the IC50 of the
SKOV-3 cells to correspond to a 2:2 cisplatin:rhTRAIL ratio,
since this produced B50% cell viability (44.58%) (Table 2).
Gene Expression Analysis
We analyzed the expression of seven genes (TNFRSF10B,
TNFRSF10C, TP53TG5, MDM2, BAX, BCL-2 and CASPASE-8)
following treatment of each cell line with cisplatin or rhTRAIL
alone, or treatment with a combination of cisplatin and
rhTRAIL. The SKOV-3 cells exhibited down-regulation of
all genes studied in response to each treatment, with a
few exceptions: the rhTRAIL treatment resulted in the up-
regulation of TNFRSF10B and CASPASE-8, while cisplatin
and combined treatments resulted in the up-regulation of
TP53TG5 (Figure 2A).
The TOV-21G cells were characterized by a different gene
expression profile than that used for the SKOV-3 cells.
Figure 1 - Viability of the SKOV-3 and the TOV-21G cell lines in response to different concentrations of cisplatin (1A) and rhTRAIL (1B)
tested. The concentrations of cisplatin used varied from 100 ug/mL to 275 mg/mL. The concentrations of rhTRAIL used varied from 0.78
mg/ml to 200 ng/ml.
Table 2 - Concentrations of cisplatin and rhTRAIL tested for the SKOV-3 cell line and cell viabilities obtained.
Proportion Cisplatin concentration (ug/mL) rhTRAIL concentration (ng/mL) Cell viability (%)
1/1 271 196.5 28.49
2/2 135.5 98.2 44.58
3/3 90.3 65.5 64.43
4/4 67 49.1 81.51
5/5 54.2 39.3 56.64
10/10 27.1 19.6 71.38
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In TOV-21G cells treated with cisplatin alone, only TP53TG5
and CASPASE-8 were up-regulated, while in presence of
rhTRAIL alone or combined with cisplatin, CASPASE-8 and
BAX were up-regulated and BCL-2 was down-regulated
(Figure 2B). In addition, TP53TG5 was up-regulated while
M2D2 was down-regulated in the presence of cisplatin alone
and in combination with rhTRAIL in both cell lines (Figures 2A
and 2B).
Thus, different gene expression profiles were observed
between both cell lines treated with rhTRAIL alone. Similar
profiles were observed for all genes when the cells were
treated with cisplatin alone or combined with rhTRAIL,
except for CASPASE-8 and BAX, respectively.
Clustering of the gene expression results observed for
the TOV-21G and the SKOV-3 cell lines highlighted genes
that revealed molecular signatures specific to each cell line
and treatment type. Upon cisplatin treatment, we obser-
ved increased expression of TP53TG5 in both cell lines
(Figure 3A). However, the expression of TP53TG5 was
approximately 100-fold higher in TOV-21G cells compared
to that in the SKOV-3 cells. Increased expression of TNFRSF
10B and CASPASE-8 in the SKOV-3 cells and CASPASE-8 in
the TOV-21G cells were highlighted as molecular markers of
the rhTRAIL treatment response (Figure 3B). When consid-
ering the combination of cisplatin and rhTRAIL, CASPASE-8
may be highlighted as a molecular marker of the synergistic
effect observed on the TOV-21G cell viability (Figure 3B).
’ DISCUSSION
OC comprises a set of neoplasms with distinct clinico-
pathological and molecular features and clinical outcomes.
Recently, studies on molecular genetics have led to the
development of a dualistic model (Type I vs. Type II) for the
characterization of Epithelial OC (EOC) (20). Type I typically
represents large tumors confined to the ovary that are
indolent and are associated with good prognosis. They are
relatively genetically stable and rarely contain TP53 muta-
tions. Type II tumors are normally advanced (stages III-IV)
when diagnosed. They are characterized by rapid growth
and are extremely aggressive, with high chromosomal insta-
bility and mutations in TP53 in495% of the cases (20). TP53
is a tumor suppressor gene that encodes a transcription
Figure 2 - Relative expression analyses of the TNFRSF10B, TNFRSF10C, TP53TG5, MDM2, BAX, BCL-2 and CASPASE-8 genes in the TOV-
21G AND the SKOV-3 cells treated with cisplatin and rhTRAIL alone, or in combination. Gene expression profiles were different in both
cell lines treated with rhTRAIL alone. Treatment with cisplatin alone or in combination with rhTRAIL led to differences in the expression
of CASPASE-8 or BAX genes, respectively.
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factor involved in cellular stress responses which is activated
in response to DNA damage by genotoxic agents.
Despite the heterogeneity observed in OC, all cases are
treated as a single disease (20,21). The standard treatment is
an invasive surgery followed by platinum-taxane chemother-
apy. Platinum-resistance occurs in many patients, there-
fore the chance of survival past five years is B30% (22).
Recently, efforts have been made to identify biomarkers for
new therapeutic strategies to overcome current therapeutic
limitations.
In this study, we used the SKOV-3 and the TOV-21G cell
lines as models of EOC in order to study the effects of
cisplatin and rhTRAIL on the apoptosis-related gene expres-
sion. TOV-21G is derived from a primary clear cell carcinoma
(grade 3, stage III), contains the wild-type TP53, and is
representative of a type I tumor. SKOV-3 originates from
metastatic cells (ascites) of an ovary adenocarcinoma and is
characterized by platinum-resistance, mutations in TP53,
thus representing a type II tumor.
Differences in cell viability were observed in both cell lines
treated with cisplatin and rhTRAIL. The SKOV-3-associated
IC50 values were calculated as 270.83 ug/mL for cisplatin
and 196.5ng/mL for rhTRAIL. However, variation in cell
viability was observed upon treatment of the TOV-21G cells
with cisplatin or rhTRAIL, therefore the IC50 values could
not be accurately determined. It was not possible to observe
the dose-response effects, as increased drug concentration
did not affect the cell viability proportionally. Karbownik
et al. (23) tested the physical and chemical stability of cisplatin
(1 mg/mL), using High-Performance Liquid Chromatography
(HPLC) for 30 days, and observed that the average concen-
tration decreased to 92.09%. Considering that more than 30
Figure 3 - Cluster analysis of TNFRSF10B, TNFRSF10C, TP53TG5, MDM2, BAX, BCL-2 and CASPASE-8 genes in the TOV-21G and the SKOV-
3 cells treated with cisplatin or rhTRAIL alone, or in combination. Following cisplatin treatment, TP53TG5was up-regulated in both cell
lines, while CASPASE-8 was up-regulated in the TOV-21G cells. Following rhTRAIL treatment, CASPASE-8 and TNFRSF10B up-regulation
was observed in the SKOV-2 cells and CASPASE-8 up-regulation was observed in the TOV-21G cells. Combined cisplatin-rhTRAIL
treatment up-regulated CASPASE-8 in the TOV-21G cells.
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days of drug storage was necessary for the establishment of
the TOV-21G cell cultures and performance of cytotoxic assays,
changes in the cisplatin stability may explain the results
obtained by the MTT assay.
Gene expression analyses in both cell lines revealed a hete-
rogeneous transcriptional activity of TNFRSF10B, TNFRS
F10C, TP53TG5, MDM2, BAX, BCL-2 and CASPASE-8, which
may reveal functional features of the SKOV-3 and the TOV-
21G cell lines that may explain our results. High expression
of TP53TG5 was observed in the TOV-21G cells, correspond-
ing to a 100-fold increase compared to the levels observed in
the SKOV-3 cells. TP53 regulates the expression of TP53TG5,
a negative regulator of cell growth that functions in cell cycle
arrest (35,36). Activated TP53 promotes transactivation of its
targets that are implicated in the induction of cell cycle arrest
and/or apoptosis, indicating that TP53 plays a critical role in
the DNA damage response (24). The TOV-21G cells express a
wild-type TP53, and the changes in TP53TG5 expression
observed in these cells after exposure to a genotoxic drug
imply that TP53 is actively involved in repair. This also may
explain the variation in cell viability observed in the TOV-
21G cells treated with cisplatin.
Upon treatment with rhTRAIL, defective drug capture by
the TNFRSF10C and TNFRSF10D TRAIL receptors may explain
the failure in determining the IC50 for this drug. Our gene
expression assays detected TNFRSF10C up-regulation in the
TOV-21G cells, which corroborates this hypothesis. In addi-
tion, TNFRSF10D can activate the NF-kB signaling through
adapter proteins such as TRAF2 and RIPK1, which interact
with the TNFRSF10D truncated intracytoplasmic domain.
Activation of this pathway has implications in cell survival
(16,25). TNFRSF10D was not evaluated in this study, how-
ever, this concept may have led to the results obtained herein.
The IC50 values observed in the SKOV-3 cells may be
related to the fact that the mutated TP53 in this cell line was
unable to perform repair. Thus, the high proliferative rate of
these cells may cause the exposure of more cells to chemo-
therapy. This phenomenon has been described in clinical
practice, wherein type II tumors that were more aggressive
than type I tumors displayed better responses to chemother-
apy due to their rapid growth (20).
Analysis of the gene expression following cisplatin
treatment demonstrated up-regulation of TP53TG5 in the
TOV-21G cells (characterized by a wild-type TP53). These
data suggest TP53 may have responded to DNA stress by
transactivating its targets. It has been reported that TP53 has
been involved in the induction of many genes related to
apoptosis, including TRAIL death and defectives receptors
(26). Almodóvar et al. (27) analyzed the expression of TRAIL
receptors in the MCF-7 (TP53 wild-type) and the EVSA-T
(TP53-mutated) breast cancer cell lines before and after
treatment with doxorubicin. Doxorubicin binds DNA and
interrupts replication, a mechanism of action similar to that
by cisplatin. In the MCF-7 cells, TNFRSF10A, TNFRSF10B
and TNFRSF10C receptor expression was increased upon
doxorubicin treatment, whereas this profile was not obser-
ved in the EVSA-T cells treated with doxorubicin. This sug-
gests that TP53 may induce the expression of these receptors
in the MCF-7 cells. In our study, increased expressions of
TNFRSF10B and TNFRSF10C receptors after cisplatin treat-
ment was not observed. Despite that the TOV-21G cells (TP53
wild-type) showed lower expressions of TNFRSF10B and
TNFRSF10C receptors , other mechanisms may be invol-
ved in the control of expression of the TRAIL receptor in
ovarian tumors.
Apoptosis is regulated in part by BCL-2 genes, which
promote cell survival and the expression of the pro-apoptotic
protein BAX (28). Considering these two targets are antago-
nistic in the apoptosis pathway, BAX:BCL-2 expression ratios
were calculated to define the apoptotic profile of both cell
lines in response to cisplatin and rhTRAIL treatments. Ratios
greater than one represent a pro-apoptotic profile, while
ratios lower than one represent an anti-apoptotic profile
(28,29,30). The ratio between BAX and BCL-2 expression in
the TOV-21G cells treated with cisplatin was 3.37. This,
together with the up-regulation of TP53 and CASPASE-8,
demonstrates a pro-apoptosis signaling profile in this cell
line, even in the absence of a dose-response effect. In the
SKOV-3 cells treated with cisplatin, the BAX:BCL-2 ratio
was 0.64, reflecting an anti-apoptotic profile of this cell
line. However, according to ATTC, the SKOV-3 cells were
platinum-resistant. The same results were observed with
respect to the rhTRAIL treatment and targets related to the
TRAIL drug response. The BAX:BCL-2 ratio in the SKOV-3
cells was 0.75; whereas the ratio was 4.86 in the TOV-21G
cells, despite that the up-regulation of TNFRSR10B in the
presence of its ligand was stronger in the SKOV-3 cells than
that in the TOV-21G cells. TNFRSF10B is the functional
receptor, however it was not expressed sufficiently to induce
the SKOV-3 cell death. This may be explained by the fact that
mRNA expression levels do not reflect the protein expression
on the cell surface (31). In addition, according to ATTC, the
SKOV-3 cells were resistant to tumor necrosis factor. Seol
et al. (32) suggest that this cell line may activate many
resistance mechanisms, one of which may be related to the
up-regulation of the defective receptor, TNFRSF10C. How-
ever, this was not directly observed in this study.
A synergistic effect between cisplatin and rhTRAIL was
observed in our cytotoxicity assays and confirmed by an
increase in the BAX:BCL-2 ratio in the TOV-21G (56.42 ratio)
and the SKOV-3 (20.34 ratio) cells. In order to determine
whether this synergism was due to the gene expression
changes, a data clustering analysis was performed. However,
genetic signatures were not revealed. Several studies have
reported that increased transcription of the TNFRSF10A and
TNFRSF10B receptors is related to the response to the DNA-
damaging chemotherapeutic agents such as cisplatin, dox-
orubicin, and etoposide in several cell types (33,34). Using
MTT cytotoxicity assays in the SKOV-3 cells, Cuello et al. (7)
demonstrated that combining TRAIL and cisplatin in
different doses was more effective than the individual use
of the molecules. They also evaluated the mRNA and protein
expressions of TNFRSF10A and TNFRSF10B in response to
the combined treatment with TRAIL and cisplatin. Despite
up-regulation of these receptor genes after combined treat-
ment, protein expression was not significantly altered.
Duiker et al. (19) also evaluated the synergistic effects of
cisplatin and rhTRAIL on gene expression in the cisplatin-
sensitive (A2780) and the cisplatin-resistant (CP70) OC cell
lines. They demonstrated that the synergism between these
drugs was associated with changes to CASPASE-8 expression
rather than increased TNFRSF10B receptor expression. We
observed up-regulation of CASPASE-8 and down-regulation
of TNFRSF10B in both cell lines treated with a combination
of both drugs, corroborating with the data described by
Duiker et al. (19).
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’ CONCLUSION
CASPASE-8 and TNFRSF10B expression may predict the
response of OC cell lines to rhTRAIL alone or in combina-
tion with cisplatin. Our study suggests that BCL-2 and BAX
expression may be helpful in the assessment of the prolif-
erative rate potential of OC cell lines, and highlighted that the
development of new therapeutic strategies for the OC should
focus on the individual molecular and genetic characteristics
of different tumor subtypes. In light of these findings, our
future research will aim to explore the exact mechanism
behind the synergy between cisplatin and rhTRAIL.
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